The 2018 congress of the European Society of Cardiology (ESC) recently concluded and has re-affirmed the exceptional status of this globe-spanning scientific endeavour. Society sources report that over five days, delegates from more than 150 countries presented, discussed or attended 4,500 abstracts in 500 expert sessions covering 400 cardiology topics. A total of 92 late-breaking science studies were presented including 17 Late Breaking Clinical Trials, six Clinical Trial Updates, and 20 Registries: these are extraordinary numbers.
Exceptional also is the calibre of the materials now being brought into the public domain. In the arena of acute heart failure the VERDICT trial produced the perhaps surprising but undoubtedly important finding that very early diagnosis and treatment in patients with non-ST segment elevation acute coronary syndrome was not superior to a strategy of assessment deferral: postponing invasive examination and treatment for up to 72 hours appears to be successful as a very early approach.
In parallel with these mainstream activities, the practical tutorials lectures were a great success, with high rates of attendance. In three full days, a faculty of 17 acknowledged experts dealt purposefully and informatively with major themes relating to the use of inodilators, particularly levosimendan, in acute and advanced heart failure. All the presentations, including the Q&A sessions which followed all lectures, were recorded and may be viewed freely at www.acuteHF.com.
View the ESC 2018 presentations in the Acute and Advanced Knowledge Centre.
Professor Gerhard Pölzl highlights Hospitalisation for the management of acute decompensation being a critical moment in the trajectory of heart failure (HF) and one that has gloomy prognostic implications for many patients.
Professor Gerhard Pölzl highlights the LION-Heart and LAICA clinical trials.
Professor Gerhard Pölzl discusses the Heart Failure Association of the European Society of Cardiology annual meeting, where several sessions were held on the use of levosimendan in heart failure.
Professor Gerhard Pölzl discusses the interplay between the acutely compromised heart and the kidneys and how the optimal treatment for individual cases is complex.
The HFA-ESC has issued a fresh position paper [Crespo-Leiro MG et al. Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1236]. Here’s our first take on some highlights.
If we had a way to reduce the risk of life-threatening complications after cardiac surgery would we use it? Of course we would. It is for reason that this blog post highlights the recent work of Dr. Qiang and colleagues. See the details here.
Professor Gerhard Pölzl reports primary results from the LION-HEART study in the management of advanced heart failure where among secondary endpoints, patients treated with levosimendan experienced a reduction in the rate of HF-related hospitalisation compared with placebo.
Professor Cynthia M Dougherty and colleagues outline an array of options for the treatment of advanced heart failure (HF) that create – quite reasonably – the impression that we are in a golden age of therapeutic possibilities for this difficult condition.
Thoughts from the expert meeting organised by the Heart Failure Clinic, Attikon University Hospital, 2018.
Alternatively login via
Back to epgonline.org